Using optical genome mapping to diagnose blood cancers
Optical Genome Mapping in Hematological Malignancies
This study is testing if a new method called optical genome mapping can help doctors diagnose blood cancers like myelodysplastic syndromes and acute lymphoblastic leukemia more accurately.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Sex | All |
| Sponsor | University Hospital, Brest Academic / other |
| Locations | 4 sites (Brest and 3 other locations) |
| Trial ID | NCT05009537 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the diagnostic capabilities of optical genome mapping in patients suspected of having hematological malignancies, such as myelodysplastic syndromes (MDS) and acute lymphoblastic leukemia (ALL). The study will involve collecting samples from patients for analysis in a chromosomal genetics laboratory. By assessing the genetic information obtained through optical genome mapping, researchers hope to improve the accuracy of diagnoses in hematologic cancers.
Who should consider this trial
Good fit: Ideal candidates include minors and adults with suspected hematologic malignancies who are undergoing diagnostic testing.
Not a fit: Patients under judicial protection or those who refuse to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate and timely diagnoses for patients with blood cancers.
How similar studies have performed: While the use of optical genome mapping is a relatively novel approach in this context, similar studies in other areas of oncology have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Minor/Major Patients * Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made. * No objection made or consent given Exclusion Criteria: * Patients under judicial protection (guardianship, curatorship, ...), * Refusal to participate
Where this trial is running
Brest and 3 other locations
- CHRU de Brest — Brest, France (Recruiting)
- CH Morlaix, service d'hémato clinique — Morlaix, France (Recruiting)
- CHIC, service d'hémato clinique — Quimper, France (Recruiting)
- CH St Brieuc, service d'hémato clinique — Saint-Brieuc, France (Recruiting)
Study contacts
- Study coordinator: Marie-Bérengère, TROADEC, PhD
- Email: Marie-berengere.troadec@chu-brest.fr
- Phone: (33)230338055
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.